CANbridge Pharmaceuticals Inc.

DB:MF1 Stock Report

Market Cap: €133.2m

CANbridge Pharmaceuticals Management

Management criteria checks 4/4

CANbridge Pharmaceuticals' CEO is James Xue, appointed in Jan 2018, has a tenure of 8.58 years. total yearly compensation is CN¥4.33M, comprised of 72.7% salary and 27.3% bonuses, including company stock and options. directly owns 7.03% of the company’s shares, worth €9.37M. The average tenure of the management team and the board of directors is 2.9 years and 5.7 years respectively.

Key information

James Xue

Chief executive officer

CN¥4.3m

Total compensation

CEO salary percentage72.66%
CEO tenure8.6yrs
CEO ownership7.0%
Management average tenure2.9yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has James Xue's remuneration changed compared to CANbridge Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025CN¥4mCN¥3m

CN¥15m

Sep 30 2025n/an/a

-CN¥61m

Jun 30 2025n/an/a

-CN¥136m

Mar 31 2025n/an/a

-CN¥289m

Dec 31 2024CN¥7mCN¥5m

-CN¥443m

Sep 30 2024n/an/a

-CN¥425m

Jun 30 2024n/an/a

-CN¥408m

Mar 31 2024n/an/a

-CN¥393m

Dec 31 2023CN¥10mCN¥6m

-CN¥379m

Sep 30 2023n/an/a

-CN¥416m

Jun 30 2023n/an/a

-CN¥453m

Mar 31 2023n/an/a

-CN¥468m

Dec 31 2022CN¥13mCN¥5m

-CN¥483m

Sep 30 2022n/an/a

-CN¥733m

Jun 30 2022n/an/a

-CN¥982m

Mar 31 2022n/an/a

-CN¥1b

Dec 31 2021CN¥10mCN¥4m

-CN¥1b

Sep 30 2021n/an/a

-CN¥1b

Jun 30 2021n/an/a

-CN¥1b

Mar 31 2021n/an/a

-CN¥828m

Dec 31 2020CN¥6mCN¥4m

-CN¥846m

Dec 31 2019CN¥10mCN¥3m

-CN¥218m

Compensation vs Market: James's total compensation ($USD642.16K) is about average for companies of similar size in the German market ($USD824.30K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James Xue (56 yo)

8.6yrs
Tenure
CN¥4,330,000
Compensation

Dr. Qun Xue, Ph D., M.B.A., also known as James, has served as Chairman of the Board and Chief Executive Officer at CANbridge Pharmaceuticals Inc. since January 2018 and as an executive Director on June 21...

Leadership Team

NamePositionTenureCompensationOwnership
Qun Xue
Founder8.6yrsCN¥4.33m7.03%
€ 9.4m
Lillian Zhang
Senior Director & Head of Finance Operations and Controller1.6yrsno datano data
Joe Shen
Chief Operating Officer1.6yrsno datano data
Qian Ma
Vice President5.2yrsno datano data
Chris Chen
Senior Vice President of Human Resourcesno datano datano data
Gerald F. Cox
Chief Development Strategist & Interim Chief Medical Officer7.1yrsno datano data
Rebecca Zhang
Chief Regulatory Advisor4yrsno datano data
Jeff Kou
Head of Clinical Operations and Senior Director of R&D Strategy & Portfolio Management4.6yrsno datano data
Jason West
Head of Global Gene Therapy Researchno datano datano data
Will Wang
Executive Director of Production1.8yrsno datano data
Suya Gao
Acting Head of Commercial Operations of Mainland China1.6yrsno datano data
Zhong Donghui
Senior Director of Regulatory Affairs & Head of Regulatory Affairs Department1.6yrsno datano data
2.9yrs
Average Tenure

Experienced Management: MF1's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Qun Xue
Founder8.6yrsCN¥4.33m7.03%
€ 9.4m
James Arthur Geraghty
Independent Non-Executive Director8.1yrsCN¥323.00k0.12%
€ 156.6k
Peng Kuan Chan
Independent Non-Executive Director5.2yrsCN¥323.00kno data
Richard Gregory
Independent Non-Executive Director6.3yrsCN¥323.00kno data
Guangping Gao
Member of Strategic Advisory Board6.2yrsno datano data
Mark Alan Goldberg
Member of Strategic Advisory Boardno datano datano data
Wei Zhao
Non-Executive Director1.2yrsno datano data
Lan Hu
Independent Non-Executive Director4.5yrsCN¥323.00kno data
Tingwei Wang
Non-Executive Director1yrno datano data
5.7yrs
Average Tenure
59.5yo
Average Age

Experienced Board: MF1's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/14 01:15
End of Day Share Price 2026/08/14 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CANbridge Pharmaceuticals Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Haoyuan ZhangChina Merchants Securities (HK) Co., Ltd
Yue-Kwong LuiJefferies LLC
Sean WuMorgan Stanley